

Immunological characterization of the OncoPig model and detection of cell-mediated immune responses to cancer



Nana H. Overgaard, Daniel R. Principe, Jeanne T. Jakobsen, Laurie A. Rund, Paul J. Grippo, Gregers Jungersen, Lawrence B. Schook

BACKGROUND

Immunotherapy has recently shown great breakthroughs; but the majority of preclinical studies has been based solely on rodent models, and it is now well established that mice “lie” and often poorly mimic many human diseases¹. Therefore, the translation of therapies to human patients can be troublesome. Due to the high degree of similarities in both the immunome, metabolism, and size between humans and pigs², there is a great potential in using pigs as a large animal model for translational cancer research³. The Immunoscore is a new approach for staging cancer patients, which underlines the importance of the immune status within the tumor microenvironment and how it affects both patient’s outcome and response to therapies⁴. For this reason, it is crucial to know the immunological landscape of the tumors in order to push the therapeutic developments forward.

THE ONCOPIG MODEL


The OncoPig is a novel transgene porcine model which, following an injection with the adenovirus encoding a Cre recombinase (AdCre), will start expressing KRAS^{G12D} and TP53^{R167H}; two mutations commonly found in human patients. This will subsequently result in tumor formation at any desired place⁵.

CONCLUSIONS

Taken together, our results show that the established OncoPig tumors are infiltrated by T cells exhibiting an either cytotoxic or regulatory phenotype, thus indicative of a tumor microenvironment mimicking the complexity seen in human patients. Additionally, we were able to measure cell-mediated immune responses to cancer in this novel, large animal model, and both the cytokine production and tumor-specific killing hence underline the potential in using the OncoPig for future testing of immune therapies against human cancer.


RATIONALE: A large animal model enables a more efficient translation of preclinical immunotherapies to human patients.

Figure 1. OncoPig tumors are heavily infiltrated by T cells




AdCre injection results in tumor formation. KRAS^{G12D} expression in tumor biopsies was detected by flow cytometry and tumor-infiltrating CD3⁺ cells were detected by both immunohistochemistry and immunofluorescence.

Figure 2. CD8β⁺ T cells specifically infiltrate the tumors



Flow cytometric detection of T cell subsets in blood samples and tumor biopsies obtained from OncoPigs 21 days post AdCre injection. Immunofluorescence staining on tumor sections was used to detect both CD3⁺ and CD8α⁺ T cells.


Figure 3. The tumor microenvironment contains cytotoxic and regulatory T cells



Intracellular flow cytometry was used to detect both perforin⁺ and FoxP3⁺ T cells in circulation and in tumor biopsies.

Detection of Granzyme B⁺ cells in the tumor was done using immunofluorescence.

Figure 4. Autologous tumor cells are specifically killed by the immune cells



In vitro fluorescence-based cytotoxicity assay with tumor cells (eFluor450⁺) and control cells (eFluor670⁺) being co-cultured with effector cells. Samples were harvested at 10 min (baseline) and 24 h post co-culturing and flow cytometry was used to reveal the percentage specific killing of tumor cells.

REFERENCES

1. Seok et al., *Proc.Natl.Acad.Sci.*, 2013
2. Dawson et al., *BMC Genomics*, 2013
3. Overgaard et al., *Front Genet*, 2015
4. Galon et al., *J Transl Med*, 2012
5. Schook et al., *PLoS One*, 2015

Contact details: nanov@vet.dtu.dk